Cargando…

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?

BACKGROUND: Inactivated poliovirus vaccine (IPV) alone does not induce mucosal immunity. However, it was hypothesized that administration of IPV together with bivalent (types 1+3) oral poliovirus vaccine (bOPV) may stimulate mucosal cross-immunity to poliovirus type 2 (PV2). METHODS: Cuban infants w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Resik, Sonia, Tejeda, Alina, Mach, Ondrej, Fonseca, Magile, Diaz, Manuel, Alemany, Nilda, Heng Hung, Lai, Aleman, Yoan, Mesa, Ileana, Garcia, Gloria, Sutter, Roland W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206124/ https://www.ncbi.nlm.nih.gov/pubmed/30376088 http://dx.doi.org/10.1093/cid/ciy604

Ejemplares similares

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies
por: Resik, Sonia, et al.
Publicado: (2015)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks()
por: Estivariz, Concepcion F., et al.
Publicado: (2023)

Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine — Worldwide, 2013–2016
Publicado: (2015)

Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region
por: Tevi-Benissan, Carol, et al.
Publicado: (2017)

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar
por: Razafindratsimandresy, Richter, et al.
Publicado: (2018)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Bangladesh
por: Estivariz, Concepcion F, et al.
Publicado: (2017)

Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
por: Hu, Yuemei, et al.
Publicado: (2019)

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization
por: Sarnquist, Clea, et al.
Publicado: (2018)

The Switch From Trivalent to Bivalent Oral Poliovirus Vaccine in the South-East Asia Region
por: Bahl, Sunil, et al.
Publicado: (2017)

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2018)

Inactivated Poliovirus Vaccine Closing the Type 2 Immunity Gap in Vietnam
por: Huyen, Dang Thi Thanh, et al.
Publicado: (2022)

Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization
por: Okayasu, Hiromasa, et al.
Publicado: (2017)

Mucosal immunity to poliovirus
por: Connor, Ruth I., et al.
Publicado: (2021)

Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
por: Hird, Thomas R., et al.
Publicado: (2012)

Immunogenicity of Fractional Dose Inactivated Poliovirus Vaccine in India
por: Ahmad, Mohammad, et al.
Publicado: (2021)

Achieving High Poliovirus Antibody Seroprevalence in Areas at Risk of Vaccine-Derived Poliovirus Transmission—Niger Experience
por: Ousmane, Sani, et al.
Publicado: (2021)

Fractional-dose inactivated poliovirus vaccine, India
por: Haldar, Pradeep, et al.
Publicado: (2019)

Effect of Inactivated Poliovirus Vaccine Campaigns, Pakistan, 2014–2017
por: Grassly, Nicholas C., et al.
Publicado: (2018)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Regulatory Aspects of Sabin Type 2 Withdrawal From Trivalent Oral Poliovirus Vaccine: Process and Lessons Learned
por: Decina, Daniela, et al.
Publicado: (2017)

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal()
por: Harutyunyan, Vachagan, et al.
Publicado: (2023)

The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines
por: Jia, Siyue, et al.
Publicado: (2020)

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame
por: Parker, Edward PK, et al.
Publicado: (2015)

Succeeding in New Vaccine Introduction: Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Cameroon, Kenya, and Nigeria
por: Scotney, Soleine, et al.
Publicado: (2017)

High resolution identity testing of inactivated poliovirus vaccines
por: Mee, Edward T., et al.
Publicado: (2015)

Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine
por: Shin, Woo-Jin, et al.
Publicado: (2018)

Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey
por: Trueba, Gabriel, et al.
Publicado: (2022)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Estimating the Extent of Vaccine-Derived Poliovirus Infection
por: Wringe, Alison, et al.
Publicado: (2008)

The Case for Live Poliovirus Vaccination
por: Paul, John R.
Publicado: (1960)

Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians’ perspectives in the endgame plan for polio eradication
por: Galal, Nermeen M., et al.
Publicado: (2018)

Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines
por: Alipon, SweetC B, et al.
Publicado: (2022)

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria
por: Verma, Harish, et al.
Publicado: (2018)

A Survey to Assess Serological Prevalence of Poliovirus Antibodies in Areas With High-Risk for Vaccine-Derived Poliovirus Transmission in Chad
por: Gamougam, Kadidja, et al.
Publicado: (2021)

Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique
por: de Deus, Nilsa, et al.
Publicado: (2020)

Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan
por: Saleem, Ali Faisal, et al.
Publicado: (2017)

A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_76oehvui81a8iqkm2v7rs0hlam